e-learning
resources
ERJ
2016
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
ERJ June Podcast: unfavourable effects of oral anticoagulants on survival in idiopathic pulmonary fibrosis
Source:
Eur Respir J 2016; 47:E66
Journal Issue:
June
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
ERJ June Podcast: unfavourable effects of oral anticoagulants on survival in idiopathic pulmonary fibrosis. Eur Respir J 2016; 47:E66
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
ERJ
March Podcast: Novel therapies in idiopathic pulmonary fibrosis
Source: Eur Respir J, 53 (3) 19E5303; 10.1183/13993003.E5303-2019
Year: 2019
Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis
Source: Eur Respir J 2016; 47:1776-1784
Year: 2016
Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns
Source: Eur Respir J 2016; 48: 1524-1526
Year: 2016
Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns
Source: Eur Respir J 2016; 48: 1523-1524
Year: 2016
ERJ August Podcast: management of chronic thromboembolic pulmonary hypertension
Source: Eur Respir J 2016; 48: E68
Year: 2016
LATE-BREAKING ABSTRACT: Detrimental effects of medically indicated oral anticoagulation on survival in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases
Year: 2015
ERJ January Podcast: clinical guidelines for chronic pulmonary aspergillosis
Source: Eur Respir J 2016; 47: E61
Year: 2016
Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients?
Source: Eur Respir Rev 2011; 20: 201-207
Year: 2011
Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study
Source: Eur Respir J 2012; 40: 101-109
Year: 2012
Late Breaking Abstract - Survival and course of lung function in patients with idiopathic pulmonary fibrosis with or without antifibrotic treatment: long-term results of the INSIGHTS-IPF registry
Source: International Congress 2019 – Idiopathic pulmonary fibrosis and surroundings
Year: 2019
Early COVID-19 lockdown in Greece and idiopathic pulmonary fibrosis: a beneficial “impact” beyond any expectation
Source: Eur Respir J, 57 (3) 2003111; 10.1183/13993003.03111-2020
Year: 2021
Triple therapy in idiopathic pulmonary fibrosis: an alarming press release
Source: Eur Respir J 2012; 39: 805-806
Year: 2012
Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis
Source: ERJ Open Res, 7 (3) 00321-2021; 10.1183/23120541.00321-2021
Year: 2021
Japanese guideline for the treatment of idiopathic pulmonary fibrosis 2017
Source: International Congress 2017 – IPF: from the bench to the bedside
Year: 2017
All-case post-marketing surveillance (PMS) of pirfenidone in Japan: Clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Warfarin and survival in people with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2007; 30: Suppl. 51, 246s
Year: 2007
Long-term outcomes of antifibrotic treatments in patients with idiopathic pulmonary fibrosis: Real-world experience
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
Clinical experience with Nintedanib for treatment of idiopathic pulmonary fibrosis (IPF) in Spain.
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
Late Breaking Abstract - Effectiveness and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) from a large Italian practice cohort
Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias
Year: 2018
The development of a measure to better understand patient experiences with pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept